Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $294.0.

  • China Pharma Holdings' Interest & Investment Income fell 7986.3% to $294.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3125.0, marking a year-over-year decrease of 6012.0%. This contributed to the annual value of $6641.0 for FY2024, which is 59.07% up from last year.
  • As of Q3 2025, China Pharma Holdings' Interest & Investment Income stood at $294.0, which was down 7986.3% from $422.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Interest & Investment Income peaked at $6655.0 during Q1 2022, and registered a low of $294.0 during Q3 2025.
  • Its 5-year average for Interest & Investment Income is $1517.0, with a median of $1240.0 in 2022.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first skyrocketed by 153916.26% in 2022, then crashed by 8575.51% in 2023.
  • Over the past 5 years, China Pharma Holdings' Interest & Investment Income (Quarter) stood at $1412.0 in 2021, then decreased by 28.97% to $1003.0 in 2022, then soared by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then plummeted by 77.98% to $294.0 in 2025.
  • Its Interest & Investment Income was $294.0 in Q3 2025, compared to $422.0 in Q2 2025 and $1074.0 in Q1 2025.